knowledge score among trainees ($p<0.05$). The project has also provided a platform for sharing experiences and maintaining partnerships with regional and international institutes in addition to provision of technical support for newly established RECs.

**Conclusion** We believe that the array of activities conducted through this project had enhanced the governance, coordination, feasibility and, efficiency of the ethical review system in Sudan.

**OC 8717 TRANSFER OF LEADERSHIP, WHAT DO WE NEED?**

Stellah Mpagama. Kilimanjaro Infectious Diseases Hospital, Kilimanjaro, Tanzania

10.1136/bmjgh-2019-EDC.41

**Background** The Pan African Consortium for the Evaluation of Anti-Tuberculosis Antibiotics (PanACEA) was designed to build clinical tuberculosis (TB) trial capacity whilst conducting clinical trials investigating novel and existing agents to shorten and simplify TB treatment. One of the objectives of the programme is to foster leadership development in sub-Saharan TB-endemic countries to move leadership to African partners in the PanACEA research programmes.

**Methods and results** In PanACEA 1 the participation of the sites on the consortium board was important to foster leadership development. African investigators now make up a large part of the consortium leadership and are actively developing new concepts. Delegates of the sites visited the annual PanACEA General Assembly meetings, where they could gain knowledge, actively participate in the meetings and discussions and network with others from the TB research community. Various sites participated at TB research community conferences (e.g. CROI, Lung Health Meeting) where PanACEA members gave presentations and could collaborate with other TB trial networks.

In PanACEA 2 all clinical trials are co-led by a European established researcher and an African Principal Investigator (PI), to ensure that African scientists are trained and mentored to lead in every aspect essential to clinical trial delivery, from trial and data management to statistical analysis and trial design, and from financial management to laboratory science. The capacity development cores, which serve as operational support for all PanACEA studies and provide high level oversight, also use the European and African countereystem, including senior and junior co-chairs among the African trial sites.

An example of leadership transfer is a large EDCTP application for the development of a new compound in MDR TB (FACE-MDR-TB) in which Stellah Mpagama is the lead applicant.

**Conclusion** The PanACEA consortium has actively facilitated a transfer of leadership programme which may be successful in future consortia.

**OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA**

1 Abdoulaye Djimde*, on behalf of the WANECAM II consortium, 2 Martin P Grobusch, 4 Reilla Zoleko Manego, 4 Ghyslain Mombo-Ngoma, 3 Stephane Picot, 1 Issaika Sagara, 6 Colin Sutherland, 1 Aminatou Kone, 6 Ogboara K Doumbot, 3 Jose Pedro Gil, 5 Anders Björkman, 7 Steffen Bornmann, 3 Issaika Soulama, 3 Bakary Fofana, 4 Stephan Duparc, 3 Alasane Diak, 3 David Hughes, 3 Cornelis Winnips, 2 Sodomon B Sirima, 3 Eric Adelhossi, 1 Jean-Bosco Ouedraogo, 1 Laurent Dembele, 3 Isaka Zongo.

1 Sophie Bignaen, 2 Edtite Iliboubo-Sangoy, 3 Aminata Fofana. University des Sciences, des Techniques et des Techniques de Bamako (USTTB), Mali; 1 Groupe de Recherche Action en Santé (GRAS), Burkina Faso; 2 Institut des Sciences et Techniques (INSTech), Ouagadougou Burkina Faso; 3 Centre de Recherches Médicales en Lamberiné (CERME), Libreville, Gabon; 4 University Abdou Moumuni of Namay, Niger; 5 Academic Medical Center (AMC), Amsterdam, The Netherlands; 6 University Lyon 1, France; 7 London School of Hygiene and Tropical Medicine, UK; 8 Karolinska Institute (KI), Stockholm, Sweden; 9 Novartis Pharma AG, Basel, Switzerland; 10 Medicines for Malaria Venture (MMV), Geneva, Switzerland; 11 Eberhard Karls Universität Tübingen, Germany

10.1136/bmjgh-2019-EDC.42

**Background** Despite major progress in the past decade, malaria remains a major public health problem in sub-Saharan Africa. West and Central Africa account for nearly 2/3 of the burden currently attributable to falciparum malaria. Artemisinin-based